J
Jinming Zhang
Researcher at Chengdu University of Traditional Chinese Medicine
Publications - 135
Citations - 3877
Jinming Zhang is an academic researcher from Chengdu University of Traditional Chinese Medicine. The author has contributed to research in topics: Medicine & Chemistry. The author has an hindex of 27, co-authored 97 publications receiving 2087 citations. Previous affiliations of Jinming Zhang include University of Macau.
Papers
More filters
Journal ArticleDOI
Mechanisms of antifungal and anti-aflatoxigenic properties of essential oil derived from turmeric (Curcuma longa L.) on Aspergillus flavus
TL;DR: The suppression effect of fungal contamination in maize indicated that turmeric EO has potential as an eco-friendly antifungal agent.
Journal ArticleDOI
A systematic review on the rhizome of Ligusticum chuanxiong Hort. (Chuanxiong)
TL;DR: The aim of this review is to present the up-to-date information on the ethnobotany, ethnopharmacological uses, phytochemicals, pharmacological activities, toxicology of this plant to identify their therapeutic potential and directs future research opportunities.
Journal ArticleDOI
Chinese herbal medicine-derived compounds for cancer therapy: A focus on hepatocellular carcinoma
TL;DR: Herbal compounds derived from CHM are of much significance in devising new drugs and providing unique ideas for the war against HCC, and it is proposed that these breakthrough findings may have important implications for targeted-HCC therapy and modernization of CHM.
Journal ArticleDOI
pH-sensitive polymeric nanoparticles for co-delivery of doxorubicin and curcumin to treat cancer via enhanced pro-apoptotic and anti-angiogenic activities.
Jinming Zhang,Jingjing Li,Zhi Shi,Yang Yang,Xi Xie,Simon Ming-Yuen Lee,Yitao Wang,Kam W. Leong,Meiwan Chen +8 more
TL;DR: P pH-sensitive nanoparticles, composed by d-α-tocopheryl polyethylene glycol 1000-block-poly (β-amino ester) (TPGS-PAE) polymers, have been fabricated for doxorubicin (Dox) and curcumin (Cur) co-delivery, which exhibited diverse anticancer approaches, i.e. pro-apoptosis and antiangiogenesis.
Journal ArticleDOI
Hyaluronic acid-coated PEI-PLGA nanoparticles mediated co-delivery of doxorubicin and miR-542-3p for triple negative breast cancer therapy.
TL;DR: HA/PEI-PLGA nanoparticles have the potential to co-deliver chemotherapeutic agents and tumor suppressive miRNAs in combinatorial TNBC therapy and may represent a promising new therapy to treat breast cancer patients in the near future.